Loading stock data...

Kimia Biosciences Ltd.

BSE: KIMIABL

BSE
37.38 -1.08 (-2.81%)

Prev Close

38.46

Open Price

40

Volume

52,548

Today Low / High

36.54 / 40

52 WK Low / High

35.1 / 86.85

Range

36 - 39

The stock is currently available for trading on the Bombay Stock Exchange (BSE). Its price is 37.38, reflecting a change of -1.08 (-2.80811%). The expected target range on the BSE is 36 - 39. The stock is showing a downward trend on the BSE. This could indicate a potential risk for investors who are considering buying at this moment.

22 Aug 40.00 -6.55%
21 Aug 38.02 1.16%
20 Aug 39.95 0.08%
19 Aug 40.26 -0.77%
18 Aug 45.37 -8.55%
14 Aug 45.14 -3.94%
13 Aug 41.99 2.41%
12 Aug 42.68 -3.89%
11 Aug 44.88 -4.90%
08 Aug 46.31 -4.99%
07 Aug 46.31 0.00%
06 Aug 48.74 0.00%
05 Aug 51.30 0.00%
04 Aug 55.00 -1.82%
01 Aug 58.40 -4.88%
31 Jul 61.99 -5.68%
30 Jul 62.71 -1.87%
29 Jul 66.00 -4.98%
28 Jul 67.61 -2.38%

Kimia Biosciences Ltd. Graph

Kimia Biosciences Ltd. Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges

If you are looking for the target price for Kimia Biosciences Ltd. T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 37.38, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.

Scenario Price Target Range
Bullish Scenario 37.38 37.75 33.98 - 41.53
38.13 30.50 - 45.75
38.50 26.95 - 50.05
Bearish Scenario 37.38 37.01 33.31 - 40.71
36.63 29.31 - 43.96
36.26 25.38 - 47.14

Overview of Kimia Biosciences Ltd.

ISIN

INE285U01025

Industry

Medical - Pharmaceuticals

Vol.Avg

20,592

Market Cap

1,768,548,726

Last Dividend

0

Official Website

Visit Website

IPO Date

DCF Diff

44.48

DCF

-7

Financial Ratios Every Investor Needs

Stock Rating Details for KIMIABL

Metric Value Recommendation
Overall Rating B- Neutral
DCF Score 1 Strong Sell
ROE Score 5 Strong Buy
ROA Score 5 Strong Buy
Debt-to-Equity (DE) Score 1 Strong Sell
Price-to-Earnings (PE) Score 2 Sell
Price-to-Book (PB) Score 1 Strong Sell

Annual Financial Income Report

Date Revenue Co.Rev GP GPR R&D Expenses G&A Expenses Operating Income Net Income EPS EBITDA NIR
2025-03-31 118.44 Cr 94.76 Cr 23.69 Cr 0.2000 0.00 Cr 0.00 Cr 16.39 Cr 9.61 Cr 2.03 21.05 Cr 0.0812
2024-03-31 104.88 Cr 100.86 Cr 4.02 Cr 0.0383 0.00 Cr 0.00 Cr -3.78 Cr -5.31 Cr -1.12 0.68 Cr -0.0506
2023-03-31 128.14 Cr 126.02 Cr 2.12 Cr 0.0165 0.00 Cr 0.00 Cr -7.15 Cr -9.35 Cr -1.98 -4.81 Cr -0.0730
2022-03-31 124.63 Cr 119.77 Cr 4.86 Cr 0.0390 6.38 Cr 0.00 Cr -2.51 Cr -3.70 Cr -0.78 1.56 Cr -0.0297
2021-03-31 132.71 Cr 120.95 Cr 11.76 Cr 0.0886 6.16 Cr 0.00 Cr 6.47 Cr 5.10 Cr 1.08 8.38 Cr 0.0385

Annual Financials Balance Sheet

Date C&C Equ. Tot. Assets Tot. Liab. Stock. Equity Tot. Debt Net Debt Inv. PP&E (Net) Curr. Def. Rev. Non-Curr. Def. Rev. LT Invest. Curr. Liab.
2025-03-31 0.21 Cr 113.32 Cr 103.36 Cr 9.9661 Cr 39.36 Cr 39.15 Cr 35.91 Cr 31.34 Cr 3.79 Cr 0.85 Cr 0.00 Cr 81.8250 Cr
2024-03-31 0.53 Cr 99.97 Cr 99.64 Cr 0.3310 Cr 43.71 Cr 43.17 Cr 31.43 Cr 32.38 Cr 0.00 Cr 0.00 Cr 0.26 Cr 69.4377 Cr
2023-03-31 0.50 Cr 123.19 Cr 117.72 Cr 5.4628 Cr 52.92 Cr 52.42 Cr 48.55 Cr 34.19 Cr 2.31 Cr 1.85 Cr 0.00 Cr 76.3978 Cr
2022-03-31 0.52 Cr 111.06 Cr 96.18 Cr 14.8883 Cr 45.50 Cr 44.99 Cr 37.23 Cr 35.08 Cr 1.70 Cr 2.35 Cr 0.00 Cr 61.8018 Cr
2021-03-31 1.67 Cr 107.42 Cr 88.99 Cr 18.4364 Cr 49.41 Cr 47.74 Cr 23.92 Cr 34.53 Cr 0.61 Cr 2.85 Cr 0.00 Cr 50.9482 Cr

Annual Financials Cash Flow Statement

Date Operating Cash Investing Cash Financing Cash Free Cash Cash Change Cash at End CapEx Income Debt Repay Dividends Inventory
2025-03-31 15.4245 Cr -4.6873 Cr -10.6787 Cr 10.8253 Cr 0.0000 Cr 0.2061 Cr -4.5992 Cr 9.6124 Cr -10.6787 Cr 0.0000 Cr -3.7796 Cr
2024-03-31 10.9970 Cr -1.5093 Cr -9.5179 Cr 9.4903 Cr 0.0359 Cr 0.5344 Cr -1.5067 Cr -5.3087 Cr 0.0000 Cr 0.0000 Cr 17.4303 Cr
2023-03-31 -9.5104 Cr -2.8204 Cr 12.3036 Cr -12.3224 Cr -0.0188 Cr 0.4985 Cr -2.8120 Cr -9.3522 Cr 0.0000 Cr 0.0000 Cr -11.2157 Cr
2022-03-31 4.6708 Cr -0.7382 Cr -1.0721 Cr 1.0910 Cr -1.1566 Cr 0.5173 Cr -3.5798 Cr -3.7030 Cr 0.0000 Cr 0.0000 Cr -13.3310 Cr
2021-03-31 3.5421 Cr -13.6563 Cr 10.4690 Cr -10.0186 Cr 0.9007 Cr 1.6739 Cr -13.5607 Cr 5.1044 Cr 0.0000 Cr 0.0000 Cr -3.3749 Cr

Quarterly Financial Income Report

Date Revenue Co.Rev GP GPR Operating Income Net Income EPS EBITDA NIR
2025-03-31 38.24 Cr 28.09 Cr 10.15 Cr 0.2654 7.30 Cr 1.99 Cr 0.42 8.62 Cr 0.0521
2024-12-31 30.10 Cr 21.71 Cr 8.39 Cr 0.2786 4.18 Cr 4.57 Cr 0.97 5.42 Cr 0.1518
2024-09-30 28.18 Cr 21.56 Cr 6.61 Cr 0.2347 2.58 Cr 1.61 Cr 0.34 3.74 Cr 0.0573
2024-06-30 22.40 Cr 16.55 Cr 5.85 Cr 0.2610 2.81 Cr 1.44 Cr 0.30 3.79 Cr 0.0642
2024-03-31 30.30 Cr 23.62 Cr 6.69 Cr 0.2206 3.35 Cr 1.80 Cr 0.38 4.16 Cr 0.0592

Quarterly Financials Balance Sheet

Date Cash & Equiv. Short-Term Inv. Cash & Short-Term Net Receivables Inventory Total Curr. Assets PP&E (Net) Total Assets Total Liabilities
2025-03-31 0.21 Cr 0.47 Cr 0.68 Cr 37.66 Cr 35.91 Cr 75.29 Cr 31.34 Cr 113.32 Cr 103.36 Cr
2024-12-31 0.18 Cr 0.44 Cr 0.63 Cr 30.38 Cr 31.31 Cr 65.12 Cr 30.19 Cr 101.85 Cr 93.90 Cr
2024-09-30 0.33 Cr 0.44 Cr 0.78 Cr 24.96 Cr 33.68 Cr 61.76 Cr 31.01 Cr 98.92 Cr 95.54 Cr
2024-03-31 0.53 Cr 0.00 Cr 0.53 Cr 28.29 Cr 30.80 Cr 61.41 Cr 32.38 Cr 99.97 Cr 99.64 Cr
2023-12-31 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr

Quarterly Financials Cash Flow Statement

Date Net Income Operating Cash Flow Investing Cash Flow Financing Cash Flow Net Cash Change Cash at End Cash at Beginning CapEx Free Cash Flow
2023-12-31 -1.95 Cr 1.64 Cr 0.00 Cr 0.00 Cr 1.64 Cr 2.22 Cr 0.58 Cr 0.00 Cr 1.64 Cr
2023-09-30 -2.44 Cr -2.44 Cr 0.00 Cr 0.00 Cr -2.44 Cr 0.58 Cr 3.02 Cr 0.00 Cr -2.44 Cr
2023-06-30 -2.71 Cr -2.71 Cr 0.00 Cr 0.00 Cr -3.21 Cr -2.71 Cr 0.50 Cr 0.00 Cr -2.71 Cr
2023-03-31 -6.17 Cr -6.17 Cr 0.00 Cr 0.00 Cr -6.17 Cr 0.50 Cr 6.66 Cr 0.00 Cr -6.17 Cr
2022-12-31 -3.46 Cr -3.46 Cr 0.00 Cr 0.00 Cr -4.07 Cr -3.46 Cr 0.61 Cr 0.00 Cr -3.46 Cr

Splits History

Date Label Split Ratio
No split history data available.

Similar Stocks: Medical - Pharmaceuticals

Company Name Symbol Price Market Cap Volume
MedPlus Health Services Limited MEDPLUS ₹821.25 ₹98,339,283,675.00 ₹72,992.00

Key Executives

Company Secretary & Compliance Officer
Ms. Pallavi Garg

Gender: female

Year Born:

Chief Operating Officer
Subrat Satpathy

Gender: Not Specified

Year Born: 1975

Assistant General Manager of Finance & Accounts
Mr. Mathura Datt Joshi

Gender: male

Year Born: 1973

Manager of Marketing
Ruchita Gopal Mishra

Gender: Not Specified

Year Born: 1990

Chief Human Resources Officer
Asit Tanaji Bhalerao

Gender: Not Specified

Year Born: 1982

Head of Research & Development
Dr. Mukesh Kumar Sharma

Gender: Not Specified

Year Born: 1968

Advisor of Strategy & IPR Head of Intellectual Property Rights
Dr. Rita Sarin

Gender: Not Specified

Year Born:

Chief Executive Officer, Chairman of the Board & MD
Mr. Sameer Goel

Gender: male

Year Born: 1975

FAQs about Kimia Biosciences Ltd.

Who is the CEO of the company?

The CEO is Sameer Goel.

What is the current market price of the stock?

The current price is ₹37.38.

What is the 52-week price range?

The range is ₹35.1-86.85.

What is the market capitalization of the company?

The market capitalization is ₹176.85 crores.

What is the Price-to-Earnings (P/E) ratio?

The P/E ratio is 18.40.

Which sector does the company belong to?

The company operates in the Healthcare sector.

What does the company do?

Overview of Kimia Biosciences Ltd. (ISIN: INE285U01025) is a leading Medical - Pharmaceuticals in India. With a market capitalization of ₹176.85 crores and an average daily volume of 20,592 shares, it operates in the Medical - Pharmaceuticals. The company last declared a dividend of ₹0.

Welcome to the Investing and Trading Information platform: InvesTrack.in

Note: This platform is for educational and informational purposes only. Do not consider anything as financial advice.

QUICK LINKS

Home
About us
Contact us
Privacy Policy
Disclaimer
Sitemap
Investing
Trading
Top Brokers
Tools
Live Analysis

STAY CONNECTED

Follow Us On Social Media
Get Latest Update On Social Media
Facebook Instagram Twitter

General Disclaimer: InvesTrack is an educational platform and not any type of investment advisory platform. Our Blog and videos are based on countless hours of research and experience, which you can use as a guide for your research purposes. None of our content should be considered a piece of investment advice. Earning Disclosure: InvesTrack is a community supported platform. We may earn a commission when you make a purchase through one of our links at no extra cost to you. Note: We are not SEBI Registered Advisors. This website is purely for training and educational purposes. We shall not be responsible for your profit or loss.

© Copyright 2024 - 2025 | InvesTrack